[ARTICLE] The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease

  • Recherche,
  • Santé-Sciences-Technologie,
Metabolomics & Alzheimer's disease
Metabolomics & Alzheimer's disease

le 6 avril 2021

Collaborative research project led by Dr. Sylvie Chalon


Alzheimer's disease (AD) leads to the progressive loss of memory and other cognitive functions. It is the most common form of dementia in the elderly and has become a major public health problem due to the increase in life expectancy. Although the detection of AD is based on several neuropsychological tests, imaging and biological analyses, none of these biomarkers allows a clear understanding of the pathophysiological mechanisms involved in the disease, and no efficient treatment is currently available. Metabolomics, which allows the study of biochemical alterations underlying pathological processes, could help to identify these mechanisms, to discover new therapeutic targets and to monitor the therapeutic response and disease progression. In this review, we have summarized and analyzed the results from a number of studies on metabolomics analyses performed in biological samples originated from the central nervous system, in AD subjects and in animal models of this disease. This synthesis revealed modified expression of specific metabolites in pathological conditions which allowed the identification of significantly impacted metabolic pathways both in animals and humans, such as the arginine biosynthesis and the alanine, aspartate and glutamate metabolism. We discuss the potential biochemical mechanisms involved, the extent to which they could impact the specific hallmarks of AD, and the therapeutic approaches which could be proposed as a result.


Biomarker; Metabolite; Metabolomic pathway; Neurodegeneration.

Contact :
Dr. Sylvie Chalon :